who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

Thermo Fisher Scientific (TMO) earnings date & Q3 2026 results

US GAAP · quarter ended 09/26/2026 · released Oct 21

Net income attributable to Thermo Fisher Scientific Inc.

$1,721M

up 6.5% y/y

Revenues

$12,137M

up 9.1% y/y

Operating income

$2,263M

up 16.6% y/y

Next report

~ Jan 28

not announced yet

The quarter in brief

Revenue grew 9% to $12.14 billion with 6% organic growth, and GAAP operating income rose 17% to $2.26 billion; operating margin widened to 18.6% from 17.4%. Net income attributable to the company rose 6.5% to $1,721 million and diluted EPS grew 9% to $4.64 from $4.27.

Key growth driver: Amortization of acquisition-related intangibles rose to $519 million from $435 million, and interest expense increased to $417 million from $347 million. · by the Q3 2026 report

All figures in $M.

Sankey diagram of TMO (Thermo Fisher Scientific) earnings report for Q3 2026: revenue, costs and profitRevenues$12,137 · +9.1%Cost of revenues$6,945 · +7.3%Selling, generalandadministrativeexpenses$1,863 · +3.8%Amortization ofacquisition-relatedintangible assets$519 · +19.3%Research anddevelopmentexpenses$348 · +0.6%Restructuring andother costs$199 · +47.4%Operating income$2,263 · +16.6%18.6% marginInterest income$252 · +7.7%Interest expense$417 · +20.2%Otherincome/(expense)$10 · +400%Income beforeincome taxes$2,088 · +14.3%Provision for income taxes$352 · +70.0%16.9% effective rateEquity inearnings/(losses) ofunconsolidated entities$9 · vs $2Net income attributable tononcontrolling interests$6 · +20.0%Net income attributable toThermo Fisher ScientificInc.$1,721 · +6.5%$4.64/sh · 14.2% margin
Sankey diagram of TMO (Thermo Fisher Scientific) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Revenues$12,137 · +9.1%
Cost of revenues$6,945 · +7.3%
Selling, general and administrative expenses$1,863 · +3.8%
Amortization of acquisition-related intangible assets$519 · +19.3%
Research and development expenses$348 · +0.6%
Restructuring and other costs$199 · +47.4%
Operating income$2,263 · +16.6% · 18.6% margin
Interest income$252 · +7.7%
Interest expense$417 · +20.2%
Other income/(expense)$10 · +400%
Income before income taxes$2,088 · +14.3%
Provision for income taxes$352 · +70.0% · 16.9% effective rate
Equity in earnings/(losses) of unconsolidated entities$9 · vs $2
Net income attributable to noncontrolling interests$6 · +20.0%
Net income attributable to Thermo Fisher Scientific Inc.$1,721 · +6.5% · $4.64/sh · 14.2% margin

Verdict: Revenue grew 9% to $12.14 billion with 6% organic growth, and GAAP operating income rose 17% to $2.26 billion; operating margin widened to 18.6% from 17.4%. Net income attributable to the company rose 6.5% to $1,721 million and diluted EPS grew 9% to $4.64 from $4.27.

In the first nine months of 2026 the company repurchased $4,000 million of its stock and paid $511 million in dividends. Third-quarter free cash flow was $2,115 million versus $1,840 million a year earlier.

Source and notation

Source: Thermo Fisher Scientific press release, 8-K EX-99.1 of 10/21/2026 (SEC EDGAR).

Open as an image: Thermo Fisher Scientific (TMO), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Thermo Fisher Scientific (TMO) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/tmo. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/tmo"><img src="https://whoreportstoday.com/t/tmo/img/thermo-fisher-scientific-tmo-earnings-sankey.png" alt="Thermo Fisher Scientific (TMO) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/tmo">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/tmo/img/thermo-fisher-scientific-tmo-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/tmo">Thermo Fisher Scientific (TMO) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Thermo Fisher Scientific Inc. is an American life science and clinical research company. · Text: Wikipedia, CC BY-SA 4.0, abridged

It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

Company reports

Q3 2026latest breakdownRevenue grew 9% to $12.14 billion with 6% organic growth, and GAAP operating income rose 17% to $2.26 billion
Q2 2026A solid, broad-based quarter with revenue up 10% and GAAP operating margin expanding to 17.4%, powered by Laboratory…

Company guidance

The company reaffirmed its outlook, no figures in the release.

Same quarter a year ago (ended December 31, 2025): revenue $12.21B, EPS (GAAP) $5.21

How we calculate

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

Guidance comes from the company's earnings release (Form 8-K filed Oct 21, 2026); every figure is checked against the release text.

The company's release on SEC EDGAR (8-K exhibit) ↗

TMO earnings history: past report dates

Oct 21, 2026 Wed6:03 ambefore market openSep 26, 2026$12.1B+9% y/y$4.64+9% y/y
Jul 23, 2026 Thu6:04 ambefore market openJun 27, 2026$12.0B+10% y/y$4.68+9% y/y
Apr 23, 2026 Thu6:03 ambefore market openMar 28, 2026$11.0B+6% y/y$4.43+11% y/y
Jan 29, 2026 Thu6:02 ambefore market openDec 31, 2025≈$12.2B+7% y/y≈$5.21+9% y/y
Oct 22, 2025 Wed6:05 ambefore market openSep 27, 2025$11.1B+5% y/y$4.27+0% y/y
Jul 23, 2025 Wed6:03 ambefore market openJun 28, 2025$10.9B+3% y/y$4.28+6% y/y
Apr 23, 2025 Wed6:04 ambefore market openMar 29, 2025$10.4B+0% y/y$3.98+15% y/y
Jan 30, 2025 Thu6:03 ambefore market openDec 31, 2024≈$11.4B+5% y/y≈$4.78+14% y/y
Oct 23, 2024 Wed6:03 ambefore market openSep 28, 2024$10.6B+0% y/y$4.25−4% y/y
Jul 24, 2024 Wed6:03 ambefore market openJun 29, 2024$10.5B−1% y/y$4.04+15% y/y
Apr 24, 2024 Wed6:03 ambefore market openMar 30, 2024$10.3B−3% y/y$3.46+4% y/y
Jan 31, 2024 Wed6:02 ambefore market openDec 31, 2023≈$10.9B−5% y/y≈$4.20+5% y/y
Oct 25, 2023 Wed6:03 ambefore market openSep 30, 2023$10.6B−1% y/y$4.42+17% y/y
Jul 26, 2023 Wed6:02 ambefore market openJul 1, 2023$10.7B−3% y/y$3.51−17% y/y
Apr 26, 2023 Wed6:04 ambefore market openApr 1, 2023$10.7B−9% y/y$3.32−41% y/y
Feb 1, 2023 Wed6:05 ambefore market openDec 31, 2022≈$11.4B+7% y/y≈$4.01−4% y/y
Show all 16 reports since 2023Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Thermo Fisher Scientific: 15-year financials

202544,5567,7466,7046,293636
202442,8797,3376,3357,267583
202342,8576,8595,9956,927523
202244,9158,3936,9506,911455
202139,21110,0287,7256,789395
202032,2187,7946,3756,815337
201925,5424,5943,6964,047297
201824,3583,7832,9383,785266
201720,9182,9602,2253,497237
201618,2742,4582,0222,814238
201516,9652,3361,9752,519241
201416,8902,5031,8942,192235
201313,0901,6101,2731,728216
201212,5101,4821,1781,724142
201111,5591,2511,3301,4300

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Thermo Fisher Scientific: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
2025110,34353,40739,1729,85228,70715,189
202497,32149,58431,0724,00922,13713,332
202398,72646,73534,7278,07724,58914,012
202297,15443,97834,2788,52425,22917,010
202195,12340,79334,6704,47720,11313,436
202069,05234,50721,72810,32521,95710,304
201958,38129,67517,7522,39911,8936,197
201856,23227,58619,6832,10310,6256,147
201756,66925,41321,9681,3359,4217,048
201645,90821,54017,5807867,0214,866
201540,83421,35012,5224525,7414,146
201442,85220,54814,5641,3446,5405,350
201331,86316,85610,7675,8269,8813,126
201227,44515,4657,1248064,8352,093
201126,83415,0387,0281,0164,8223,113

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

9 months ended 2026-09-26 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated5,8674,361+1,506
· incl. D&A (non-cash add-back)depreciation & amortization945758
· incl. stock-based comp (non-cash)share-based compensation261226
Capexpurchases of property & equipment−1,263−1,060−203
Free cash flow ≈operating cash flow − capex4,6043,301+1,303
Investing activities, netcapex, acquisitions, securities−8,874−4,938−3,936
· incl. acquisitionsbusinesses net of cash acquired−8,877−4,037−4,840
Financing activities, netdebt, buybacks, dividends−1,541−1,725+184
· incl. buybacksrepurchases of common stock−4,000−2,963−1,037
· incl. dividends paid−511−474−37
Net change in cash−4,384−2,029−2,355
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Sep 26, 2026: $54.8B (48% of total assets). Compare with other S&P 500 companies →

Corporate governance

2/2good

  • Feb 202610-K FY2025 cover: a single class of common stock; Legal Proceedings lists only product, IP, employment and commercial claims — no shareholder suits and no SEC cases. sec.gov ↗
  • Jan 2026Shares outstanding of 371.5M vs. 393.8M in February 2021 (−5.7% over 5 years); 2025 SBC of $310M, 0.7% of revenue. data.sec.gov ↗
1 more fact and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Dec 2025Dividend per share rose from $0.88 (2020) to $1.72 (2025); buybacks of $3–4B a year in 2022–2025. data.sec.gov ↗

Scoring: 2.0, no deductions: single share class, share count −5.7% over 5 years, SBC 0.7% of revenue, dividend raised every year, no shareholder suits or SEC cases = 2.0

Share classes
The 10-K cover registers a single class — Common Stock (NYSE: TMO); no deduction.
Dilution
Shares outstanding 393.8M (February 2021) → 371.5M (January 2026), −5.7%; SBC $310M = 0.7% of revenue; no deduction.
Disclosure
Full 10-K/10-Q reporting, filed on time.
Dividends
Dividend $0.88 (2020) → $1.72 (2025), raised every year; buybacks of $2–4B a year in 2021–2025; no policy breaches.
Lawsuits & regulators
Legal Proceedings in the 2025 10-K lists only product liability, IP, employment and commercial claims; no shareholder disclosure suits and no SEC cases.
Related parties
2026 proxy: related-party transactions go through the audit committee, none material disclosed; no controlling shareholder.

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap

Thermo Fisher Scientific (TMO) earnings: FAQ

When is TMO's next earnings date?

We have not yet seen an announcement of the date from Thermo Fisher Scientific (TMO). Based on last year's report on Jan 29, 2026, the next report is expected around Jan 28, 2027.

What time does TMO report earnings?

Thermo Fisher Scientific usually reports before market open: its latest results release was filed with the SEC at 6:03 am ET on Oct 21, 2026.

When did TMO last report earnings?

Thermo Fisher Scientific reported Q3 2026 results on Oct 21, 2026.

Where can I find Thermo Fisher Scientific's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to TMO's filings; this page breaks the latest report down in a Sankey chart.

What was TMO's net income in Q3 2026?

Thermo Fisher Scientific reported net income of $1,721M for Q3 2026 (+6.5% year over year), under US GAAP.

Does Thermo Fisher Scientific pay dividends?

Yes. In 2025, Thermo Fisher Scientific paid $636M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.

How has Thermo Fisher Scientific's revenue changed since 2011?

Per its 10-K filings, revenue grew 3.9x: $11,559M in 2011 and $44,556M in 2025. The peak was $44,915M in 2022. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: UHS · Q3 2026 · UNH · Q3 2026 · VEEV · Q2 FY2027 · VRTX · Q3 2026 · VTRS · Q2 2026 · WAT · Q3 2026 · WST · Q3 2026 · ZBH · Q3 2026 · ZTS · Q3 2026 · A · Q3 FY2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy